RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia

Xiao, Jinyan; Xie, Jundan; Zhou, Biqi; Liu, Yujie; Lu, Jing; Jiang, Airui; Yao, Hong; Qiu, Qiao‐Cheng; Ding, Zixuan; Xue, Shengli; Tang, Xiaowen; Qiu, Huiying; Chen, Suning; Shen, Hongjie; Wu, Depei; Xu, Yang

doi:10.1080/10428194.2023.2190433

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,6,17 Haplo-HSCT was associated with stronger graft-versus-leukemia (GVL) effect. 28,29 In consistent with previous studies, 24,26,30 our study also demonstrated that allo-HSCT can significantly improve the prognosis of AML-RUNX1 mut . Thus, allo-HSCT should be recommended for AML-RUNX1 mut .…”

Section: Discussionsupporting

confidence: 91%

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis

Wang,

Li,

Jiang

et al. 2024

Hematological Oncology

View full text Add to dashboard Cite

This study aimed to investigate the clinical characteristics and prognosis of Runt‐related transcription factor 1 (RUNX1) mutant acute myeloid leukemia (AML) patients by comparing the features of AML patients with or without RUNX1 mutation. We retrospectively analyzed 180 AML patients including 36 AML patients with mutant RUNX1(AML‐RUNX1mut) and 144 AML patients with wild‐type RUNX1(AML‐RUNX1wt) were selected using the case‐pair method(1:4). Compared to AML‐RUNX1wt, AML‐RUNX1mut showed higher frequency of ASXL1 (p < 0.001), SRSF2 (p < 0.001), BCORL1 (p < 0.001), RAS (p = 0.010) mutations, and absent NPM1 mutations (p = 0.022). The 3‐year overall survival (OS) and disease‐free survival (DFS) of AML‐RUNX1mut and AML‐RUNX1wt were 73.1% versus 68.0% (p = 0.64) and 80.7% versus 71.6% (p = 0.37), respectively. AML‐RUNX1mut receiving allogeneic hematopoietic cell transplantation (allo‐HSCT) showed better survival than those who did not receive allo‐HSCT (3‐year OS, 84.3% vs. 52.7%; p = 0.006). Multivariate analysis showed that EZH2 mutation (p = 0.003), white blood cell (WBC) ≥30 × 109/L (p = 0.036) and age ≥60 years (p = 0.038) were significant independent risk factors for inferior OS of AML‐RUNX1mut; WBC ≥30 × 109/L (p = 0.013) and DNMT3A mutation (p = 0.045) were significant independent risk factors for shorter DFS of AML‐RUNX1mut. In conclusion, AML‐RUNX1mut showed unique clinical characteristics, but the survival between AML‐RUNX1mut and AML‐RUNX1wt were comparable. EZH2 co‐mutation, DNMT3A co‐mutation, old age and high WBC count were associated with inferior survival of AML‐RUNX1mut. Allo‐HSCT can significantly improve the prognosis of AML‐RUNX1mut.

show abstract